Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Hypersensitivity. G6PD deficiency, and other cellular metabolic disorders causing haemolytic anaemia.
|
|
Special Precautions
Patients with history of atopic allergies. Children. Pregnancy and lactation. Monitoring Parameters Perform G6PD deficiency screening prior to initiation of therapy. Monitor plasma uric acid levels 4 hours after administration then every 6-8 hours until tumour lysis syndrome resolution; CBC. Monitor for signs and symptoms of hypersensitivity reactions.
|
|
Adverse Reactions
Significant: Severe haemolytic reactions, methaemoglobinaemia.
Gastrointestinal disorders: Diarrhoea, vomiting, nausea, abdominal pain, constipation, mucositis.
General disorders and administration site conditions: Fever.
Hepatobiliary disorders: Hyperbilirubinemia, increased serum ALT.
Infections and infestations: Sepsis.
Immune system disorders: IgG and IgE antibody development.
Nervous system disorders: Headache.
Metabolism and nutrition disorders: Peripheral oedema, hypophosphataemia, hypervolaemia.
Psychiatric disorders: Anxiety.
Respiratory, thoracic and mediastinal disorders: Pharyngolaryngeal pain.
Potentially Fatal: Serious hypersensitivity reactions (e.g. anaphylactic shock). |
|
CIMS Class
|
|
ATC Classification
V03AF07 - rasburicase ; Belongs to the class of detoxifying agents used in antineoplastic treatment.
|
